Table 5 univariate and multivariate analysis for OS and DFS of the patients

 Age (yrs) < 40 vs ≥40

2.2

1.0–4.8

0.038

2.8

1.3–5.9

0.006

 B symptoms -ve vs + ve

1.1

0.5–2.4

0.78

1.23

0.6–2.5

0.58

 Bulky disease + ve vs -ve

1.8

0.6–5.1

0.28

0.61

0.24–1.6

0.31

 IPS Low vs High

1.9

0.9–4.0

0.10

1.5

0.7–3.2

0.26

 Gender M vs F

1.2

0.6–2.5

0.59

1.23

0.6–2.5

0.51

 Pathology

0.9

0.5–1.6

0.73

0.86

0.49–1.5

0.61

 Stage early vs late

2.6

1.2–5.8

0.02

2.2

1.0–4.5

0.04

 CD20 -ve vs + ve

0.15

0.05–0.29

< 0.001

0.15

0.07–0.33

< 0.001

CD68 (mRNA) –ve vs + ve

13.2

3.9–43.7

< 0.001

6.6

2.7–16.0

< 0.001

 CD68 (IHC) –ve vs + ve

4.7

2.6–8.2

< 0.001

4.0

2.4–6.6

< 0.001

 CD68 CC < 10 vs ≥10 cells

12.2

4.2–32.3

< 0.001

7.1

3.1–16.4

< 0.001

 Age (yrs) < 40 vs ≥40

2.5

1.1–5.6

0.02

3.2

1.5–7.0

0.004

 Stage early vs late

2.2

0.8–6.1

0.11

1.8

0.69–4.5

0.23

 CD20 -ve vs + ve

0.24

0.09–0.69

0.008

0.29

0.11–0.74

0.01

CD68 (mRNA)–ve vs + ve

2.6

0.28–24.6

0.40

5.8

0.90–32.0

0.07

 CD68 (IHC) –ve vs + ve

5.2

0.65–41.3

01.2

8.2

1.6–41.8

0.01

 CD68+ cells (FCM) < 20 vs ≥20 cells

9.5

1.8–51.5

0.009

7.7

1.7–33.7

0.007